Racial and Ethnic Reporting and Representation in Phase III Alzheimer's Disease Clinical Trials in the US.

Abstract

Alzheimer's disease (AD) disproportionately affects racial and ethnic minoritized populations in the United States, yet these groups remain markedly underrepresented in clinical research. Phase III clinical trials are critical for informing regulatory decision and treatment guidelines, but the extent to which they report and include racial and ethnic diverse participants in the US context has not been systematically assessed. We conducted a comprehensive retrospective review of all US-based Phas